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Abstract
To investigate the contribution of glycation and oxidation reactions to the modification of insoluble collagen in aging and diabetes, Maillard reaction products were measured in skin collagen from 39 type 1 diabetic patients and 52 nondiabetic control
subjects. Compounds studied included fructoselysine (FL), the
initial glycation product, and the glycoxidation products,
N'-(carboxymethyl)lysine (CML) and pentosidine, formed
during later Maillard reactions. Collagen-linked fluorescence
was also studied. In nondiabetic subjects, glycation of collagen
(FL content) increased only 33% between 20 and 85 yr of age.
In contrast, CML, pentosidine and fluorescence increased fivefold, correlating strongly with age. In diabetic patients, collagen FL was increased threefold compared with nondiabetic
subjects, correlating strongly with glycated hemoglobin but not
with age. Collagen CML, pentosidine and fluorescence were
increased up to twofold in diabetic compared with control patients: this could be explained by the increase in glycation
alone, without invoking increased oxidative stress. There were
strong correlations among CML, pentosidine and fluorescence
in both groups, providing evidence for age-dependent chemical
modification of collagen via the Maillard reaction, and acceleration of this process in diabetes. These results support the description of diabetes as a disease characterized by accelerated
chemical aging of long-lived tissue proteins. (J. Clin. Invest.
1993. 91:2463-2469.) Key words: aging collagen * diabetesglycation * oxidation
-

Introduction
Glycation (nonenzymatic glycosylation) is a nonenzymatic,
posttranslational modification ofprotein, resulting from chemical reactions between glucose and primary amino groups (1).
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The major product in tissue proteins is fructoselysine (FL),'
formed by glycation of E-amino groups on lysine residues (Fig.
1). The extent of glycation of tissue proteins depends on the
ambient glucose concentration and is relatively constant with
age (2-4). However, products formed from FL in subsequent
Maillard or browning reactions accumulate gradually with advancing age in long-lived tissue proteins (2-4). These products
include N'-(carboxymethyl)lysine (CML) and N'-(carboxymethyl)hydroxylysine (CMhL), which are formed by oxidative cleavage of FL and glycated hydroxylysine respectively (3,
4), pentosidine, a fluorescent crosslink formed between arginine and lysine residues (5-7) (Fig. 1), as well as unidentified
compounds with characteristic Maillard-type, visible wavelength fluorescence (maxima at Ex = 328 nm, Em = 378 nm)
(4). CML, CMhL, and pentosidine have been termed "glycoxidation" products (4, 8) because both glycation and free radical
oxidation reactions are required for their formation from reducing sugars. The exact origin of these compounds, i.e., from
glucose vs. ribose (5), ascorbate (6, 7, 9), or other sugars (8), is
uncertain, although present evidence suggests that they are derived exclusively from reactions between proteins and carbohydrates (8).
According to the "glycation hypothesis" of aging and the
pathogenesis of diabetic complications, accumulation of endstage products of the Maillard reaction (also known as advanced glycosylation end-products [AGE products] ) alters the
structural properties oftissue proteins and reduces their susceptibility to catabolism ( 10, 11 ). These changes contribute to the
aging of tissues, and when accelerated by hyperglycemia, to the
gradual development of diabetic complications. Despite the
attractiveness of this hypothesis, the only Maillard products
known to accumulate with age, i.e., CML, CMhL, and pentosidine, result not from glycation alone: oxidation reactions are
also necessary for their formation (2-4, 7, 1 1 ). The development of increased fluorescence of proteins in diabetes and aging is also enhanced by oxidation reactions, and carbohydrateor lipid-dependent processes may also be involved (8). These
considerations raise questions about the relative importance of
the glycation and oxidation components of glycoxidation in
the accumulation of Maillard products in tissue proteins.
To our knowledge, no previous studies have made direct
comparisons between the concentrations and relative rates of
accumulation of the glycoxidation products CML and pentosidine in collagen from control and diabetic populations. There
is a similar lack of information on the relative contributions of
1. Abbreviations used in this paper: CMhL, N'-(carboxymethyl)hydroxylysine; CML, N'-(carboxymethyl)lysine; FL, fructoselysine; Hb,
hemoglobin.
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increased glycation vs. increased oxidation in the accumulation of these products. We have attempted to address these
issues in the present study, and show that concentrations of
CML and pentosidine, and Maillard-type fluorescence, increase in concert in human skin collagen with age, and that the
rate of their increase is accelerated, again in a concerted fashion, in diabetes. Our data also suggest that the accelerated accumulation of glycoxidation products in diabetes can be explained by hyperglycemia and increased glycation alone, without invoking an increase in oxidative stress.
Our findings support the description of diabetes as a disease
characterized by accelerated chemical modification and aging
of collagen via the Maillard reaction. The relationships between concentrations ofthese biomarkers and the presence and
severity of complications in diabetes are considered in the following article ( 12).

Methods
Diabetic patients and control subjects. A total of 91 people were
enrolled in this study: 39 patients (27 male, 12 female) with insulin-dependent (type 1) diabetes mellitus, aged 17-73 yr (41.1±15.3 yr,
mean±SD), duration ofdiabetes 0-46 yr ( 17.9±11.5 yr), and 52 nondiabetic control subjects, aged 0-85 yr (47.6±25.9 yr). The nondiabetic
control skin samples were obtained from healthy, nondiabetic donors,
or at autopsy at the Royal Victoria Hospital in Belfast, Northern Ireland. Autopsy samples were taken within 6 h of death from patients
who had died of acute illness, e.g., stillbirth, severe congenital heart
disease, trauma, or myocardial infarction. These patients had no history of diabetes and, where possible, had documented normal plasma
glucose levels during their terminal illnesses. Some analytical data on
the control patients (skin collagen FL and CML concentrations) have
been reported previously (3). Live participants in each group were
healthy and free of ailments known to elicit inflammatory responses,
such as infection, the inflammatory arthritides, or hemochromatosis.
Clinical characterization of the diabetic patients and their complication status are presented in the following article ( 12).
Skin samples. An elliptical full-thickness skin biopsy (- 0.5 x 1.0
cm) was taken from the medial aspect of the buttock (under 2% lidocaine local anesthesia in live donors). For 15% ofthe samples, insufficient collagen was available to perform all assays. Thus, the number
of samples in some analyses may not always be equal to the number of
people involved in the study. Informed consent was obtained from all
participants, and the study was approved by the Ethical and Human
Subjects Committees of the participating institutions.
-
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Pentosidine

Figure 1. Structures of FL, CML,
and pentosidine. FL is the initial
product of glycation of protein. The
glycoxidation products, CML and
pentosidine, are formed by sequential glycation and oxidation reactions between reducing sugars and
protein.

Materials. Unless otherwise indicated, reagents were of the highest
quality obtainable from Sigma Chemical Co. (St. Louis, MO). The
preparation of FL, CML, and pentosidine standards have been described previously (3, 7).
Analytical procedures. Procedures for sample storage, for isolation
of insoluble collagen by extraction with I M NaCl, 0.5 M acetic acid,
and organic solvents, and for acid hydrolysis of the collagen have been
described previously (3). FL, CML, and lysine in collagen hydrolysates
were measured as their N-trifluoroacetyl methyl esters by selected ion
monitoring gas chromatography-mass spectrometry, as described previously (3). Amounts of FL and CML were normalized to the lysine
content of the collagen by external standardization ( 13) using calibration curves generated from solutions with constant lysine content and
variable concentrations of the other analytes. Samples were analyzed in
random order without knowledge of the sample identity. Pentosidine
was measured in collagen hydrolysates by reversed-phase HPLC using
postcolumn fluorescence detection (Ex = 328 nm, Em = 378 nm), as
described previously (7). The assay was standardized with a preparation of pentosidine labeled with [4,5-3H]lysine ofknown specific radioactivity (7). Collagen-linked fluorescence was measured in collagen
solubilized by digestion with 2% pepsin in 0.5 M acetic acid for 24 h at
37°C. Fluorescence was measured at both Ex = 328 nm, Em = 378 nm
and Ex = 370 nm, Em = 440 nm, and normalized to the hydroxyproline content of collagen, measured according to Stegemann and Stalder
( 14), as modified by Maekawa et al. ( 15). Hemoglobin (Hb) A, was
measured by agar gel electrophoresis (Corning Medical, Halsted, England) after saline incubation to remove labile hemoglobin ( 16). In the
39 diabetic patients, HbA, (mean±1 standard deviation [SD]) was
11.4±2.4%, range 6.9-16.9%. In 24 of these patients, HbA1 values had
been obtained every 3 mo for 6 yr preceding the skin biopsy, as described (12). From these results, a mean HbA, (MHbA1) was determined for each patient, and this correlated with recent HbA, (r = 0.78,
P < 0.0001). The normal laboratory range for HbA, in nondiabetic
subjects (mean±2 SD) is 3.6-7.2%.
Statistical analysis. Data are shown as means± 1 SD. Correlation
analyses were performed using the linear least squares method. Statistical data are summarized in figure legends.

Results

Glycation of collagen. In a previous study of the nondiabetic
subjects (3), a slight, but statistically significant, increase in the
extent of glycation (FL content) of skin collagen with age was
observed. As shown by the lower line in Fig. 2 (from reference
3, Fig. 4), this amounted to a 33% increase in glycation of
lysine residues in skin collagen between the ages of 20 and 85 yr
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Figure 2. Effects of age and diabetes on glycation of human skin collagen. The equation of the line for control subjects aged > 20 yr (not
shown) is: mmol FL/mol Lys = [0.029 x age (yr)] + 3.27, (r = 0.54,
P < 0.001 ). There was no significant relationship between age and
skin collagen glycation in the diabetic patients.

Figure 4. Effects of age and diabetes on the concentration of CML in
human skin collagen. The equation of the line for control subjects
is: mmol CML/mol Lys =[0.0 18 x age] - 0.022 (r = 0.89, P
< 0.001); and for the diabetic patients: mmol CML/mol Lys
[0.027 X age]) - 0.015 (r =0.84, P < 0.001).

(r = 0.55, P < 0.001). The upper line in Fig. 2 illustrates that
glycation of collagen from the diabetic patients was increased
approximately threefold compared with collagen from the nondiabetic control subjects. In the diabetic group, collagen glycation did not correlate either with age or duration of diabetes (P
> 0.05). There was a significant correlation between collagen
glycation and HbAI in these patients (r = 0.74, P < 0.0001, n
= 37), confirming the results of previous studies ( 17, 18): this
correlation was strengthened when MHbAI was used in the
analysis (r = 0.89, P < 0.0001, n = 23) (Fig. 3).

Glycoxidation products and fluorescence. In previous studies, we have shown that, in contrast to FL, there is a substantial
age-dependent increase in the concentration of CML in skin
collagen from control subjects (3), i.e., about a fivefold increase between the ages of20 and 80 yr. As shown in Fig. 4, the
concentration ofCML also increases with age in collagen from
diabetic subjects, but levels of CML in collagen from diabetic
subjects are significantly greater than those found in nondiabetic subjects. Analyses for pentosidine (Fig. 5) and fluorescence (Fig. 6) also showed substantial age-dependent increases,
with higher levels in collagen from diabetic, compared with
age-matched nondiabetic, subjects. To determine the significance ofthe differences between the two groups, each measurement was expressed as a ratio of the observed value to the

=

25

20
C
c
-.

-

0

15

U)

E

3
-J

-J
LA.
-

60

.

10

-5
E

E
E

40

0
C
.UU',

5

0~

0
0

4

8

12

16

Mean HbA1 ()

Figure 3. Skin collagen glycation (FL content) in the diabetic population correlates strongly with mean percent glycation of hemoglobin
(MHbA,), an index ofglycemic control over 6 yr before skin biopsy
(r = 0.89, P < 0.0001, n = 23). The ellipse in the lower left hand
corner of the graph indicates the means (± 1 SD) of measurements of
glycation of collagen (Fig. 2) and percent HbA, from adult nondiabetic control subjects. Control HbAI values were obtained from the
laboratory reference range, derived from results for 200 nondiabetic

subjects.
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Figure 5. Effects of age and diabetes on the concentration of pentosidine in human skin collagen. The equation of the line for control
subjects is: gmol pentosidine/mol Lys = [0.41 x age] - 0.48 (r
= 0.78, P < 0.001); and for the diabetic patients: Amol pentosidine/
mol Lys = [0.93 x age] - 10.27 (r = 0.83, P < 0.001).
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Figure 6. Effects of age and diabetes on Maillard-type fluorescence
(Ex = 328 nm, Em = 378 nm) in human skin collagen. The equation
of the line for the control subjects is: fluorescence units/jig Hyp
= [0.032 x age] + 0.056 (r = 0.92, P < 0.001 ); and for the diabetic
patients: fluorescence units/,ug Hyp = [0.047 x age] - 0.047 (r
=0.86,P<0.001).

predicted value for a control subject of the same age, obtained
from the regression line for the control population (Figs. 4-6).
By these analyses (Fig. 7), the control and diabetic populations
differed significantly in age-corrected levels of FL, CML, pentosidine, and fluorescence in skin collagen (P < 0.001). In
contrast to FL, concentrations of CML and pentosidine, and
also fluorescence, correlated significantly with duration of diabetes (CML r = 0.74; pentosidine r = 0.77; fluorescence r
= 0.71, P < 0.001); these correlations persisted to varying degrees when the concentrations were standardized for age
(CMLR r = 0.34, P < 0.05; pentosidineR r = 0.75, P < 0.001;
fluorescenceR r = 0.58, P < 0.01).
The strong correlations among the various Maillard products in the control and diabetic populations are summarized in
Fig. 8. The correlations between fluorescence and pentosidine
in both groups (Fig. 8, top panel) are consistent with the observation that pentosidine accounts for 30% of the fluorescence
-

in collagen at Ex = 328 nm, Em = 378 nm (4, 7). There were
equally strong correlations between levels ofthe two glycoxidation products, CML and pentosidine, in collagen from both the
control and diabetic groups (Fig. 8, bottom panel). Similarly,
the correlations between CML and fluorescence (graph not
shown) were highly significant for both groups (control r
= 0.94, P < 0.001; diabetic r = 0.95, P < 0.001).
Choice offluorescence maxima. In many reports on "Maillard-type" fluorescence in proteins, measurements are conducted at excitation and emission wavelengths of 370 and 440
nm, respectively. The recent work identifying pentosidine as a
major Maillard reaction fluorophore (5, 7) and three-dimensional fluorescence spectra of proteins browned by glucose (4,
8) both suggest that the fluorescence characteristic ofthe Maillard reaction has excitation and emission maxima close to the
maxima for pentosidine, i.e., 328 and 378 nm, respectively. As
illustrated in Fig. 9, there is a strong correlation between fluorescence of collagen at Ex/Em = 370/440 and that at Ex/Em
= 328/378 nm. However, the fluorescence intensity is about
twice as great at Ex/Em = 328/378 nm as at Ex/Em = 370/
440 nm, providing a twofold increase in sensitivity for measurement of Maillard-type fluorescence in collagen if these wavelengths are used.

Discussion
Glycation of protein in diabetes and aging. The present data
show that glycation of collagen (FL content) is increased about
threefold in type I, insulin-dependent diabetic patients compared with age-matched nondiabetic control subjects. Glycation of skin collagen correlated with glycation of hemoglobin.
However, the correlation was stronger between collagen glycation and MHbA,, an index of average glycemia over a 6-yr
period. This provides new evidence that collagen FL may reflect glycemic control over a longer period of time than HbA,,
supporting the conclusions of an earlier study (19). In that
study, we observed that the FL content of collagen in type 1
diabetic patients can be decreased by a relatively short (4 mo)
period of improved glycemic control, but the proportional decrease in glycation was not as great for collagen as for hemoglobin. In contrast, levels of glycoxidation products and fluores-
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Figure 7. Comparison of age-normalized levels of FL, CML, pentosidine, and fluorescence in skin collagen from control subjects (C) and
diabetic pattients (D). The observed
value of each parameter for each
donor was divided by the calculated
value, based on the regression equation for the control population
(shown in the legends to Figs. 4-6),
then expressed as the ratio of observed to calculated value. Means+ 1
SD of the ratios are shown.
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cence were unaffected by improved
0ycemic control. In keeping with the conclusion that collagen FL levels are primarily
determined by medium-term (several months [19]) average
glycemia, our data demonstrate that, again in contrast to glycoxidation products or fluorescence, Amadori adducts increase
only slightly with age in both control and diabetic populations.
Changes in glycoxidation (Maillard) products andfluorescence. Comparative analyses of CML, pentosidine, and Maillard-type fluorescence in skin collagen (Figs. 4-6 ) indicate that
both glycoxidation and fluorescence are increased in collagen
from diabetic patients, compared with age-matched nondiabetic controls. The age-normalized data in Fig. 7 also indicate
significant differences between the diabetic and control populations in all parameters, independent of age. These results suggest that the increased accumulation of pentosidine (as well as
CML and fluorescence) is not confined to a subset of diabetic
patients with renal complications, as has been suggested ( I11),
but rather that it is a general feature of the disease process. The
comparisons in Fig. 8 emphasize the strong correlations among
these three parameters of chemical damage to collagen. The
fact that CML and pentosidine are so dissimilar in their structure and physical properties, yet increase in concert both with
age and in diabetes, emphasizes their common origin from

glycoxidation reactions. Because the age-dependent rate of
chemical modification of skin collagen, as measured by the
accumulation of glycoxidation products, is accelerated in the
diabetic patients, diabetes may be properly described as a disease characterized, at the chemical level, by accelerated aging
of collagen. Although CML and pentosidine are only two out
of many, as yet unidentified, products of the Maillard reaction,
they may be regarded as "biomarkers" of the overall extent of
glycoxidative aging of proteins (8) in both nondiabetic and
diabetic populations.
Role ofoxidative stress. In recent work from several laboratories (8, 20-24), oxidative stress and increased oxidative damage to biomolecules have been proposed as possible unifying
mechanisms for the development of complications in diabetes.
Although the level of glycoxidative damage to collagen is
clearly increased in the diabetic patients (Fig. 7), an important
question that can be asked from our data is whether the increased levels of glycoxidation products in collagen can be attributed solely to the increase in glycation, or whether an increase in oxidative stress is also involved. For this reason we
have attempted to predict the levels of glycoxidation products
and fluorescence in our diabetic patients, based on the age of
onset and duration of diabetes, and the relative increase in
glycemia. The assumption is made that Maillard products accumulated in collagen at a "normal" rate until the onset of
diabetes, and thereafter at an accelerated rate, the difference
being directly proportional to the increase in glycation of protein, either collagen or hemoglobin. The age of onset and duration of diabetes were known for each patient, and we used each
patient's relative increase in glycation of either collagen or hemoglobin, compared to age-matched controls, at the time of
biopsy as an indicator of long-term glycemic control. The following formula was used for the calculations:
PL

=

CR[AO + (RG X D)],

(1)

where PL = predicted level of glycoxidation product or fluorescence; CR = control rate of accumulation (per year) ofglycoxidation product or fluorescence in collagen, i.e., slope ofcontrol
(lower) line in Figs. 4-6; AO = age of onset of diabetes (years);
RG = ratio of glycation of collagen or hemoglobin (%HbA,) in
Maillard Reaction Products in Diabetes and Aging
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the patient, compared with age-matched nondiabetic control
subject; D = duration of diabetes (years).
From these calculations, ratios of observed (actual) to predicted values for each parameter were calculated. As shown in
Table I, the observed levels of each glycoxidation product and
fluorescence in diabetic skin collagen were consistently lower
than predicted. The underestimate was more marked when
based on the relative increase in glycation of collagen than
hemoglobin in diabetic patients. Also, the underestimate remained if mean HbA, values (calculated from results obtained
every 3 mo over a 6-yr period preceding the skin biopsy) were
used in the calculation. Thus, in all cases, observed levels were
lower than would be expected. We conclude that the increased
accumulation of glycoxidation products and fluorescence in
diabetic skin collagen can be explained, on average, solely by
the increase in glycation for the duration of disease: we have
found no evidence of a general increase in oxidative stress in
diabetes. Indeed, the lower than expected levels of glycoxidation products and fluorescence, i.e., the ratios of < 1.0 in Table
I, suggest that oxidative stress may actually be decreased, on
average, in diabetic patients. These analyses assume that CML,
pentosidine, and fluorescence are derived predominantly from
interactions between proteins and glucose (i.e., as opposed to
ribose or ascorbate), and that the increase in glycoxidation
products is related to the increase in average glycemia, as measured by the increase in glycation of proteins. The conclusions
are valid unless one assumes that the rate offormation of CML,
pentosidine, and increased fluorescence in collagen is primarily
determined by factors other than the extent of glycation of
proteins, e.g., variations in oxidative stress and/or levels of
carbohydrates other than glucose. Although this hypothesis
cannot be excluded, and although a possible role for increased
oxidative stress has recently been emphasized by Wolff et al.
(23), we have found a strong correlation between levels of FL
and CML in urine from diabetic patients, suggesting a relationship between glycation of protein and the formation of CML
(25). Notably, in that study, we observed that the ratio of CML
to FL was decreased in urine from diabetic, compared with
nondiabetic, subjects. Again, this is consistent with a decrease
in oxidative stress in diabetic subjects. In relation to the possibility that CML is derived to a significant extent from sources
other than glycated proteins, recent (unpublished) findings in
our laboratory have shown that plasma pentose levels are not
Table I. Ratio of Observed to Predicted Concentrations
ofGlycoxidation Products and Fluorescence in Skin Collagen
from Diabetic Patients
Basis of calculation*
Measurement

Glycation of collagen
ratio*

Glycation of hemoglobin
ratio*

CML
Pentosidine
Fluorescence

0.74±0.32
0.65±0.41
0.60±0.33

0.82±0.37
0.79±0.50
0.73±0.38

*
Ratios of observed to predicted concentrations of glycoxidation
products and fluorescence. The predicted values are calculated as described by Eq. 1 (see Discussion), using the relative increase in glycation of collagen (FL) (left column) or hemoglobin (HbA,) (right column) for individual patients (mean±SD).
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increased in type 1 diabetic patients, and that in nondiabetic
guinea pigs, ascorbate supplementation does not result in increased collagen FL, CML, or pentosidine content.
Regardless of the status of oxidative stress in diabetes, it is
clear that the net glycoxidative modification of collagen is increased. It is also evident from the large standard deviations
shown in Table I that the ratios, based on either glycation of
collagen or hemoglobin, are not normally distributed about the
mean. This implies that, although the average ratio of observed
to predicted values is < 1.0, some patients have levels of glycoxidation products and fluorescence which are much higher
than would be predicted from duration ofdiabetes and severity
of hyperglycemia. The presence of higher than average oxidative stress in these patients may be an inherent characteristic,
unrelated to the presence of diabetes. Indeed, a considerable
variation in the rates of accumulation of glycoxidation products with age, despite similar glycemia, is seen in the nondiabetic population (Figs. 4-6). Diabetic individuals who are also
under high oxidative stress and are therefore rapid accumulators of glycoxidation products may be particularly vulnerable
to the development of complications. The association between
levels of skin collagen glycoxidation products and complication status is discussed further in the following article.

Acknowledgments
The authors wish to thank Professor D. R. Hadden, Dr. L. Kennedy,
and Dr. A. B. Atkinson (Royal Victoria Hospital), and Drs. D. A. J.
Keegan, F. A. O'Connor, and W. E. Parkes (Altnagelvin Hospital) for
permission to study patients under their care. We are grateful to the
staff of the Biochemistry and Hematology Departments at the Royal
Victoria and Altnagelvin Hospitals, to Drs. D. J. Pettitt and R. L. Hanson for statistical advice, and to Drs. D. J. Pettitt and P. H. Bennett for
helpful discussions.
This work was supported in part by research grant DK-19971 from the
National Institute of Diabetes, Digestive and Kidney Diseases (USA).

References
1. Cohen, M. P. 1986. Diabetes and Protein Glycation. Springer-Verlag, Inc.
New York. 140 pp.
2. Dunn, J. A., J. S. Patrick, S. R. Thorpe, and J. W. Baynes. 1989. Oxidation
of glycated proteins: age-dependent accumulation of N'-(carboxymethyl)lysine
in lens proteins. Biochemistry. 28:9464-9468.
3. Dunn, J. A., D. R. McCance, S. R. Thorpe, T. J. Lyons, and J. W. Baynes.
1991. Age-dependent accumulation of N'-(carboxymethyl)lysine and N'-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry. 30:12051210.
4. Dyer, D. G., J. A. Blackledge, B. M. Katz, C. J. Hull, H. D. Adkisson, S. R.
Thorpe, T. J. Lyons, and J. W. Baynes. 1991. The Maillard reaction in vivo. Z.
Erndhrungswiss. 30:29-45.
5. Sell, D. R., and V. M. Monnier. 1989. Structure elucidation of a senescence
cross-link from human extracellular matrix: implication of pentoses in the aging
process. J. Biol. Chem. 264:21597-21622.
6. Grandhee, S. K., and V. M. Monnier. 1991. Mechanism of formation of the
Maillard protein cross-link, pentosidine: glucose, fructose and ascorbate as pentosidine precursors. J. Biol. Chem. 266:11649-11653.
7. Dyer, D. G., J. A. Blackledge, S. R. Thorpe, and J. W. Baynes. 1991.
Formation of pentosidine during nonenzymatic browning of protein by glucose:
identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. BioL. Chem. 266:11654-11660.
8. Baynes, J. W. 1991. Perspectives in diabetes: role of oxidative stress in
development of complications in diabetes. Diabetes. 40:405-412.
9. Dunn, J. A., M. U. Ahmed, M. H. Murtiashaw, J. M. Richardson, M. D.
Walla, S. R. Thorpe, and J. W. Baynes. 1990. Reaction of ascorbate with lysine
and protein under autoxidizing conditions: formation of Nl-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Bio-

chemistry. 29:10964-10970.

10. Monnier, V. M., R. R. Kohn, and A. Cerami. 1984. Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Nati. Acad. Sci.
USA. 81:583-587.
1 1. Sell, D. R., and V. M. Monnier. 1990. End-stage renal disease and diabetes
catalyze the formation of a pentose-derived crosslink from aging human collagen.
J. Clin. Invest. 75:380-384.
12. McCance, D. R., D. G. Dyer, K. E. Bailie, S. R. Thorpe, J. W. Baynes, and
T. J. Lyons. 1993. Maillard reaction products and their relation to complications
in insulin dependent diabetes mellitus. J. Clin. Invest. 91:2470-2478.
13. Kennedy, J. H. 1984. Analytical Chemistry. Harcourt Brace Jovanovich,
New York. 392-395.
14. Stegemann, H., and K. Stalder. 1967. Determination of hydroxyproline.
Clin. Chim. Acta. 18:267-273.
15. Maekawa, T., T. K. Rathinasamy, K. I. Altman, and W. F. Forbes. 1970.
Changes in collagen with age: the extraction of acid soluble skin collagen from the
skin of mice. Exp. Gerontol. 5:177-186.
16. Menard, L., M. E. Dempsey, L. A. Blankenstein, H. Aleyassine, M.
Wacks, and J. S. Soeldner. 1980. Quantitative determination of glycosylated
hemoglobin A, by agar gel electrophoresis. Clin. Chem. 26:1598-1602.
17. Lyons, T. J., and L. Kennedy. 1985. Nonenzymatic glycosylation of skin
collagen in patients with limited joint mobility. Diabetologia. 28:2-5.
18. Vishwanath, V., K. E. Frank, C. A. Elmets, P. J. Dauchot, and V. M.

Monnier. 1986. Glycosylation ofskin collagen in type I diabetes mellitus: correlations with long-term complications. Diabetes. 35:916-921.
19. Lyons, T. J., K. E. Bailie, D. G. Dyer, J. A. Dunn, and J. W. Baynes. 1991.
Decrease in skin collagen glycation with improved glycemic control in patients
with insulin dependent diabetes mellitus. J. Clin. Invest. 87:1910-1915.
20. Wolff, S. P. 1987. The potential role of oxidative stress in diabetes and its
complications: novel implications for theory and therapy. In Diabetic Complications. M. J. C. Crabbe, editor. Churchill Livingstone, New York. 167-220.
21. Godin, D. V., and S. A. Wohaieb. 1988. Reactive oxygen radical processes
in diabetes. In Oxygen Radicals in the Pathophysiology of Heart Disease. P. K.
Singal, editor. Kluwer Academic Publishers, Boston. 303-322.
22. Oberley, L. W. 1988. Free radicals and diabetes. Free Radical Biol. Med.
5:113-124.
23. Wolff, S. P., Z. Y. Jiang, and J. V. Hunt. 1991. Protein glycation and
oxidative stress in diabetes mellitus and ageing. Free Radical Biol. Med. 10:339352.
24. VanderJagt, D. L., B. Robinson, K. K. Taylor, and L. A. Hunsaker. 1992.
Reduction of trioses by NADPH-dependent aldo-keto reductases: aldose reductase, methylglyoxal, and diabetic complications. J. Biol. Chem. 267:4364-4369.
25. Knecht, K. J., J. A. Dunn, K. F. McFarland, D. R. McCance, T. J. Lyons,
S. R. Thorpe, and J. W. Baynes. 1991. Effect of diabetes and aging on carboxymethyllysine levels in human urine. Diabetes. 40:190-196.

Maillard Reaction Products in Diabetes and Aging

2469

